CAR T Cell Therapies for ALL and NHL

Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, discusses two abstracts being presented at ASH looking at CAR T cell therapies for the treatment of ALL and NHL.

Clinical Pearls

Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, discusses two abstracts being presented at ASH looking at CAR T cell therapies for the treatment of ALL and NHL.

  • A phase I study will be presented at ASH evaluating CAR T cell therapy directed against CD19 for the treatment of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
  • Another phase I study evaluated high dose therapy and ASCT followed by CAR T cell therapy directed against CD19 for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.